EUVIMEDEUVIMED entdecken
Open Access

Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease

Simon Lebek iD, Francesco Chemello iD, Xurde M Caravia iD, Wei Tan iD, Hui Li iD, Kenian Chen, Lin Xu iD, Ning Liu iD, Rhonda Bassel-Duby iD, Eric N Olson iD

Science · 13.01.2023 · 379 (6628) · 179-185

DOI: 10.1126/science.ade1105 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science, erschienen am 13.01.2023. Verfasst von Simon Lebek und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Hauptthemen laut MEDLINE: Gene Editing, Heart Diseases, Calcium-Calmodulin-Dependent Protein Kinase Type 2. Die Arbeit wurde bisher 124-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NICHD NIH HHS, NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

CRISPR-Cas9 gene editing is emerging as a prospective therapy for genomic mutations. However, current editing approaches are directed primarily toward relatively small cohorts of patients with specific mutations. Here, we describe a cardioprotective strategy potentially applicable to a broad range of patients with heart disease. We used base editing to ablate the oxidative activation sites of CaMKIIδ, a primary driver of cardiac disease. We show in cardiomyocytes derived from human induced pluripotent stem cells that editing the CaMKIIδ gene to eliminate oxidation-sensitive methionine residues confers protection from ischemia/reperfusion (IR) injury. Moreover, CaMKIIδ editing in mice at the time of IR enables the heart to recover function from otherwise severe damage. CaMKIIδ gene editing may thus represent a permanent and advanced strategy for heart disease therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingHeart DiseasesCalcium-Calmodulin-Dependent Protein Kinase Type 2AnimalsHumansMiceCRISPR-Cas SystemsInduced Pluripotent Stem CellsMyocytes, Cardiac

Substanzen

Calcium-Calmodulin-Dependent Protein Kinase Type 2

Autor:innen und Institutionen

  • Department of Molecular Biology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Hamon Center for Regenerative Science and Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Department of Internal Medicine II, University Hospital Regensburg, 93053 Regensburg, Germany.
  • Quantitative Biomedical Research Center, Department of Population and Data Sciences, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

ORCID-Profile: Simon Lebek, Francesco Chemello, Xurde M Caravia, Wei Tan, Hui Li, Lin Xu, Ning Liu, Rhonda Bassel-Duby, Eric N Olson

Förderung

  • NIDDK NIH HHS
  • NICHD NIH HHS
  • NHLBI NIH HHS

Zitieren

APA

Lebek, S., Chemello, F., Caravia, X. M., Tan, W., Li, H., Chen, K., Xu, L., Liu, N., Bassel-Duby, R., & Olson, E. N. (2023). Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease. Science, 379(6628), 179-185. https://doi.org/10.1126/science.ade1105

Vancouver

Lebek S, Chemello F, Caravia XM, Tan W, Li H, Chen K, et al. Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease. Science. 2023;379(6628):179-185. doi:10.1126/science.ade1105

BibTeX
@article{Lebek2023,
  author = {Lebek, Simon and Chemello, Francesco and Caravia, Xurde M and Tan, Wei and Li, Hui and Chen, Kenian and Xu, Lin and Liu, Ning and Bassel-Duby, Rhonda and Olson, Eric N},
  title = {Ablation of CaMKIIδ oxidation by CRISPR-Cas9 base editing as a therapy for cardiac disease},
  journal = {Science},
  year = {2023},
  volume = {379},
  number = {6628},
  pages = {179--185},
  doi = {10.1126/science.ade1105}
}
Kostenlos starten →